Henry Schein Inc

Henry Schein’s stock jumps after securing exclusive U.S. rights to CytoChip’s CitoCBC oncology assay—boosting revenue, innovation, and market moat.

Henry Schein Inc. is a leading health care distribution company that provides essential products and services to professionals and institutions globally, with a strong financial foundation and commitment to innovation and service excellence.

Henry Schein Inc. has announced strategic changes and reported mixed Q1 financial results, with profit exceeding expectations but revenue falling short, sparking investor interest and uncertainty about the company’s future.

Henry Schein Inc.’s stock performance has been stable, but faces scrutiny, as the company’s ability to adapt and innovate will be crucial in sustaining its market position in the health care distribution sector.